<DOC>
	<DOCNO>NCT00917501</DOCNO>
	<brief_summary>The purpose study see take substance call omega-3 fatty acid effective , safe , well-tolerated treating adolescent major depressive disorder ( also call simply `` depression '' `` clinical depression '' ) . Another purpose study see much omega-3 fatty acid patient 's blood make patient less likely develop mania ( i.e . period irritability extreme silliness accompany decrease need sleep , risky behavior , feel like patient special ability , inability sit still , rapid speech ) future . Yet another purpose study see take omega-3 fatty acid affect brain scan . Omega-3 fatty acid United States Food Drug Administration ( FDA ) -approved treat depression adult child adolescent . Omega-3 fatty acid obtain diet , often fish sea food , though also find food source flax seed . Omega-3 fatty acid show play role affect brain chemical responsible regulate mood find reduce symptom depression medicated-patients major depressive disorder . By complete study , investigator hope good understand benefit treatment , respond medication , great risk develop mental illness . With information , investigator hope able improve treatment outcome people major depressive disorder .</brief_summary>
	<brief_title>Neurochemical Effects Omega-3 Fatty Acids Adolescents Risk Mania</brief_title>
	<detailed_description>A . Specific Aims : ( 1 ) To collect pilot data regard efficacy , safety , tolerability omega-3 fatty acid supplementation treatment adolescent active depressive symptom high risk develop mania ( i.e . patient bipolar parent meet DSM-IV-TR criterion major depressive disorder ) . ( 2 ) To use proton magnetic resonance spectroscopy ( 1H MRS ) ( i.e . prefrontal neurochemistry ) red blood cell ( RBC ) omega-3 fatty acid level examine potential mediator treatment response omega-3 fatty acid adolescent high risk mania .</detailed_description>
	<mesh_term>Bipolar Disorder</mesh_term>
	<criteria>Inclusion Criterion : Ages 1021 year old . At least one biological parent bipolar I disorder . Meets DSMIVTR 80 criterion major depressive disorder ( MDD Depressive Disorder NOS screening determine Washington University St. Louis Kiddie Schedule Affective Disorders Schizophrenia , WASHUKSADS ; 81 Childhood Depression Rating ScaleRevised Version40,41 ( CDRSR ) score great equal 28 screen baseline . Fluent English . Provision write informed consent/assent previously describe . Agrees use one follow method birth control : complete abstinence sexual intercourse , barrier ( diaphragm condom ) , oral/injectable contraceptive . Exclusion Criterion : Contraindication MRI scan ( e.g. , metal clip , brace claustrophobia ) . Mood symptom result acute medical illness acute intoxication withdrawal drug alcohol determine careful medical evaluation rapid symptom resolution . Psychotic symptom ( i.e. , hallucination delusion ) . Any lifetime history manic hypomanic episode . Any lifetime diagnosis bipolar disorder otherwise specify ( NOS ) cyclothymia current diagnosis depressive disorder NOS . A current diagnosis dysthymia exclusionary , adolescent also current diagnosis MDD . A history major medical ( e.g . diabetes ) neurological illness , laboratory abnormality , significant episode ( &gt; 10 minute ) loss consciousness could influence MRS result , determine study physician . Any history alcohol drug dependence ( nicotine dependence permit ) . Allergy shellfish seafood . Mental retardation ( IQ &lt; 70 ) determine Wechsler Abbreviated Scale Intelligence ( WASI ) , administer research coordinator train psychometrician . A positive serum pregnancy test lactating . A history intolerance , hypersensitivity nonresponse omega3 fatty acid . Any history hematological disorder firstdegree relative , since omega3 fatty acid may associate anticoagulant effect . Concomitant use medication anticoagulant effect ( e.g . aspirin ) . A lithium valproate serum level &gt; 0.4 mEq/L 30 mg/L , respectively baseline . Use antipsychotic , mood stabilizer , stimulant ( opt discontinue ) , atomoxetine within 72 hour ( aripiprazole within two week exclusionary long halflife ) antidepressant within 5 day ( fluoxetine within one month exclusionary long halflife ) . Patients treat depot antipsychotic within one dose interval baseline exclude . Subjects diagnose ADHD take stable dose stimulant previous month permit continue determine necessary subject , primary caregiver , treat clinician report conjunction study physician . Concomitant use psychotropic medication medication central nervous system ( CNS ) effect within 5 halflives baseline MRI scan prior treatment medication CNS effect require 5 day screen period . Any psychiatric symptom require admission inpatient psychiatric hospital , determine study physician . Any initiated psychotherapy within 2 month prior screen visit , plan initiate psychotherapy study participation . Adolescents present current depressive episode despite longerterm psychotherapy ( i.e. , &gt; 2 month ) may include . For participant enter study psychotherapy , type frequency therapy remain constant study .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Mania</keyword>
	<keyword>Adolescents risk Mania</keyword>
</DOC>